Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Other Non-Current Assets (2022 - 2024)

Historic Other Non-Current Assets for Universe Pharmaceuticals (UPC) over the last 3 years, with Q3 2024 value amounting to $36.3 million.

  • Universe Pharmaceuticals' Other Non-Current Assets rose 10117425.83% to $36.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was $36.3 million, marking a year-over-year increase of 10117425.83%. This contributed to the annual value of $36.3 million for FY2024, which is 10117425.83% up from last year.
  • As of Q3 2024, Universe Pharmaceuticals' Other Non-Current Assets stood at $36.3 million, which was up 10117425.83% from $96141.0 recorded in Q1 2024.
  • In the past 5 years, Universe Pharmaceuticals' Other Non-Current Assets ranged from a high of $36.3 million in Q3 2024 and a low of $35864.0 during Q3 2023
  • For the 3-year period, Universe Pharmaceuticals' Other Non-Current Assets averaged around $9.7 million, with its median value being $1.3 million (2022).
  • In the last 5 years, Universe Pharmaceuticals' Other Non-Current Assets crashed by 9852.99% in 2023 and then skyrocketed by 10117425.83% in 2024.
  • Universe Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $2.4 million in 2022, then crashed by 98.53% to $35864.0 in 2023, then soared by 101174.26% to $36.3 million in 2024.
  • Its last three reported values are $36.3 million in Q3 2024, $96141.0 for Q1 2024, and $35864.0 during Q3 2023.